High potency of lipid conjugated TLR7 agonist requires nanoparticulate or liposomal formulation. (2018)

First Author: Gadd AJR

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.ejps.2018.07.048

PubMed Identifier: 30048801

Publication URI: http://europepmc.org/abstract/MED/30048801

Type: Journal Article/Review

Volume: 123

Parent Publication: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

ISSN: 0928-0987